The global Gaucher disease treatment market is anticipated to grow at a considerable CAGR of around 3% during the forecast period. Gaucher disease is a type of genetic disease caused by mutation of cells that leads to one of the enzymes in the body not working properly. The body constantly recycles itself as old cells die and new cells are made There is a long list of enzymes that are responsible for the recycling dead cells, one of which when it's not working properly leads to Gaucher disease. Gaucher disease has a lot of different symptoms out of which the most common is an enlarged liver and spleen. Currently, quite a lot of research is going on in the field regarding the treatment of Gaucher disease, which in turn, fueling the growth of the Gaucher disease treatment market.

Request a Free Sample of our Global Gaucher Disease Treatment Market: https://www.omrglobal.com/request-sample/gaucher-disease-treatment-market

However, the SBT causes any adverse reaction in patients ranging from weight loss, tremor, flatulence, abdominal pain, dyspepsia, paresthesia, influenza-like symptoms, visual disturbances, and thrombocytopenia which is lowering the popularity of SBT in the Gaucher disease market. In addition, the high cost associated with the treatment is limiting the growth of the global Gaucher disease treatment market. For instance, according to the National Institute of Health in 2018, the average wholesale prices of ERTs are $1,903 per vial for imiglucerase (400 units), $1,652 per vial for velaglucerase (400 units), and $935 per vial for taliglucerase (200 units). Patients are often administered 60 units/kg every two weeks. As this dosage, the approximate annual costs for imiglucerase, velaglucerase, and taliglucerase would be $544,260, $472,475, and $510,510, respectively.

A full Report of Global Gaucher Disease Treatment Market is Available at: https://www.omrglobal.com/industry-reports/gaucher-disease-treatment-market

Gaucher Disease Treatment Market Segmentation

By Disease Type

• Type I
• Type II
• Type III
By Treatment Type

• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Treatment (SBT)

Regional Analysis

• North America
• US
• Canada
• Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
• Asia-Pacific
• China
• India
• Japan
• Rest of Asia-Pacific
• Rest of the World

Company Profiles

• AVROBIO, Inc.
• Amicus Therapeutics
• CENTOGENE N.V.
• ERAD Therapeutics Inc.
• Genzyme Corp. (Sanofi Company)
• Greenovation Biotech GmbH
• JCR Pharmaceuticals Co., Ltd.
• Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
• Lixte Biotechnology Holdings, Inc.
• Novartis International AG
• ORPHAZYME A/S
• Oxyrane
• Pfizer Inc.
• Protalix BioTherapeutics, Inc.
• Takeda Pharmaceutical Co. Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/gaucher-disease-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404